Deslorelin vs IGF-1 LR3
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileIGF-1 LR3
IGF-1 LR3 (Long Arg3 IGF-1) is a synthetic analogue of Insulin-like Growth Factor 1 with an amino acid substitution at position 3 and a 13-amino acid N-terminal extension. These modifications prevent binding to IGF-binding proteins (IGFBPs), dramatically extending its half-life from ~12 minutes (native IGF-1) to approximately 20–30 hours. IGF-1 LR3 is widely used in research for its ability to promote cellular growth, protein synthesis, hyperplasia, and nutrient uptake into muscle tissue.
Full profile| Deslorelin | IGF-1 LR3 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | Insulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent) |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol) |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols) |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Hypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint pain |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols).
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; IGF-1 LR3 is Once daily post-workout, on training days only (common protocol).
- Research depth: this profile cites 2 sources for Deslorelin vs 3 for IGF-1 LR3.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
IGF-1 LR3
In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.